You are here

  • Home
  • Archive
  • Volume 12, Issue 4
  • Oral PD-L1 inhibitor GS-4224 selectively engages PD-L1 high cells and elicits pharmacodynamic responses in patients with advanced solid tumors

Article metrics

Article menu
Immunotherapy biomarkers
Original research
Oral PD-L1 inhibitor GS-4224 selectively engages PD-L1 high cells and elicits pharmacodynamic responses in patients with advanced solid tumors

 

Online download statistics by month:

Online download statistics by month: April 2024 to February 2026

AbstractFullPdf
Apr 2024554557217
May 2024179181101
Jun 202412412460
Jul 202416416468
Aug 202411811555
Sep 202413613755
Oct 202412612850
Nov 202416216339
Dec 202414815055
Jan 202512413048
Feb 202526826959
Mar 202516616678
Apr 202518518565
May 202516316357
Jun 2025969629
Jul 2025110
Aug 2025110
Jan 2026430
Feb 2026110
Total272027341036